2, 4, 5-Trichloro-6-((2, 4, 6-trichlorophenyl) amino) isophthalonitrile, Exerts Anti-bladder Activities through IGF-1R/STAT3 Signaling
Jiayuan Jiao, Wanqiu Wang, Haihong Guang, He Lin, Yanxin Bu, Yunhua Wang, Yi Bi, Baoshan Chai, Zhaojin Ran.
Chem Pharm Bull (Tokyo). 2019 May 01 ; 67 (5) : 410- 418.
引用產(chǎn)品: abs04175 Recombinant Human LR3 Insulin-Like Growth Factor I/LR3-IGF-1 (MG)
影響因子:1.258
Anemoside B4 exerts anti-cancer effect by inducing apoptosis and autophagy through inhibiton of PI3K/Akt/mTOR pathway in hepatocellular carcinoma
Shuyi Xue, Yu Zhou, Jin Zhang, Zhuo Xiang, Yang Liu, Ting Miao, Guoxin Liu, Bangguo Liu, Xu Liu, Lixia Shen, Zhe Zhang, Mingchun Li, Qing Miao.
Am J Transl Res. 2019 May 01 ; 11 (4) : 2580- 2589.
引用產(chǎn)品: abs47000024 Anemoside B4
影響因子:3.061
mir-19 promotes the proliferation of clear cell renal cell carcinoma by targeting the FrK–PTen axis
Zhi-Fei Jing, Jian-Bin Bi, Ze-Liang Li, Xian-Kui Liu, Jun Li, Yu-Yan Zhu, Xiao-Tong Zhang, Zhe Zhang, Zhen-Hua Li, Chui-Ze Kong.
Onco Targets Ther. 2019 Apr 10 ; 12 : 2713- 2727.
引用產(chǎn)品: abs133481 FRK Antibody
Calculus Bovis Sativus Improves Bile Acid Homeostasis via Farnesoid X Receptor-Mediated Signaling in Rats With Estrogen-Induced Cholestasis
Dong Xiang, Jinyu Yang, Yanan Liu, Wenxi He, Si Zhang, Xiping Li, Chenliang Zhang, Dong Liu.
Front Pharmacol. 2019 Feb 01 .
引用產(chǎn)品: abs123885
abs122163
abs124142 Rabbit Anti-CYP7A1 Polyclonal Antibody
abs116056 VDR Polyclonal Antibody
abs132184 beta-Actin antibody
abs131244 Lamin B Antibody
影響因子:3.831
相關(guān)產(chǎn)品
免責聲明
- 凡本網(wǎng)注明“來源:化工儀器網(wǎng)”的所有作品,均為浙江興旺寶明通網(wǎng)絡(luò)有限公司-化工儀器網(wǎng)合法擁有版權(quán)或有權(quán)使用的作品,未經(jīng)本網(wǎng)授權(quán)不得轉(zhuǎn)載、摘編或利用其它方式使用上述作品。已經(jīng)本網(wǎng)授權(quán)使用作品的,應(yīng)在授權(quán)范圍內(nèi)使用,并注明“來源:化工儀器網(wǎng)”。違反上述聲明者,本網(wǎng)將追究其相關(guān)法律責任。
- 本網(wǎng)轉(zhuǎn)載并注明自其他來源(非化工儀器網(wǎng))的作品,目的在于傳遞更多信息,并不代表本網(wǎng)贊同其觀點和對其真實性負責,不承擔此類作品侵權(quán)行為的直接責任及連帶責任。其他媒體、網(wǎng)站或個人從本網(wǎng)轉(zhuǎn)載時,必須保留本網(wǎng)注明的作品第一來源,并自負版權(quán)等法律責任。
- 如涉及作品內(nèi)容、版權(quán)等問題,請在作品發(fā)表之日起一周內(nèi)與本網(wǎng)聯(lián)系,否則視為放棄相關(guān)權(quán)利。